Search

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

Diphenidol

Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

Hydroxypropyl cellulose

As a food additive, hydroxypropyl cellulose is used as a thickener and as an emulsion stabilizer. … Hydroxypropyl cellulose is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated forming -OCH2CH(OH)CH3 groups.

L-arginine

Peanut oil

[A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]

Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (formaldehyde inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

Flavin adenine dinucleotide

(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.

Bictegravir

It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.

Elranatamab

It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

Belantamab mafodotin

In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … US marketing authorization in November 2022.